146 related articles for article (PubMed ID: 2645716)
21. A randomized trial comparing cyclosporine with antilymphoblast-globulin-azathioprine for renal allograft recipients. Results at 2 1/2-6 years.
Johnson CP; Simmons RL; Sutherland DE; Canafax DM; Ascher NL; Payne WD; Flick B; Najarian JS; Fryd DS
Transplantation; 1988 Feb; 45(2):380-5. PubMed ID: 3278431
[TBL] [Abstract][Full Text] [Related]
22. Annual trends and triple therapy--1991-2000.
Nishikawa K; Terasaki PI
Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
[TBL] [Abstract][Full Text] [Related]
23. A randomized trial comparing cyclosporine and steroids with cyclosporine, azathioprine, and steroids in cadaveric renal transplantation.
Amenábar JJ; Gómez-Ullate P; García-López FJ; Aurrecoechea B; García-Erauzkin G; Lampreabe I
Transplantation; 1998 Mar; 65(5):653-61. PubMed ID: 9521199
[TBL] [Abstract][Full Text] [Related]
24. [Factors influencing prevalence and clinical course of cytomegalovirus (CMV) infection in kidney transplant patients].
Szymczakiewicz-Multanowska AM; Kuźniewski M; Zawilińska B; Zgórniak-Nowosielska I; Uracz D; Ignacak E; Betkowska-Prokop A; Sułowicz W
Przegl Lek; 2001; 58(7-8):772-7. PubMed ID: 11769385
[TBL] [Abstract][Full Text] [Related]
25. Control of cytomegalovirus disease in renal transplant patients treated with prednisone, azathioprine and cyclosporine using intensive monitoring and decreased immunosuppression.
Gómez E; de Oña M; Mélon S; Alvarez R; Laures A; Rodríguez M; Pobes A; Alvarez-Grande J
Nephron; 1999; 82(3):238-45. PubMed ID: 10395996
[TBL] [Abstract][Full Text] [Related]
26. The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients.
Lewis RM; Johnson PC; Golden D; Van Buren CT; Kerman RH; Kahan BD
Transplantation; 1988 Feb; 45(2):353-9. PubMed ID: 2830686
[TBL] [Abstract][Full Text] [Related]
27. Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression.
Olivari MT; Diekmann RA; Kubo SH; Braunlin E; Jamieson SW; Ring WS
J Heart Transplant; 1990; 9(6):618-21. PubMed ID: 2277297
[TBL] [Abstract][Full Text] [Related]
28. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients.
Herman M; Weinstein T; Korzets A; Chagnac A; Ori Y; Zevin D; Malachi T; Gafter U
J Lab Clin Med; 2001 Jan; 137(1):14-20. PubMed ID: 11150019
[TBL] [Abstract][Full Text] [Related]
29. Mycophenolate mofetil in pancreas transplantation.
Gruessner RW; Sutherland DE; Drangstveit MB; Wrenshall L; Humar A; Gruessner AC
Transplantation; 1998 Aug; 66(3):318-23. PubMed ID: 9721799
[TBL] [Abstract][Full Text] [Related]
30. A comparison of triple-therapy with double-therapy immunosuppression in cadaveric renal transplantation.
Bowman JS; Angstadt JD; Waymack JP; Jaffers GJ
Transplantation; 1992 Mar; 53(3):556-9. PubMed ID: 1312752
[TBL] [Abstract][Full Text] [Related]
31. Reduction of infectious complications following heart transplantation with triple-drug immunotherapy.
Andreone PA; Olivari MT; Elick B; Arentzen CE; Sibley RK; Bolman RM; Simmons RL; Ring WS
J Heart Transplant; 1986; 5(1):13-9. PubMed ID: 3302153
[TBL] [Abstract][Full Text] [Related]
32. Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine: is chronic allograft nephropathy the major cause of late graft loss?
Marcén R; Pascual J; Teruel JL; Villafruela JJ; Rivera ME; Mampaso F; Burgos FJ; Ortuño J
Transplantation; 2001 Jul; 72(1):57-62. PubMed ID: 11468535
[TBL] [Abstract][Full Text] [Related]
33. Experience with cyclosporine and steroids in clinical renal transplantation.
Tilney NL; Milford EL; Araujo JL; Strom TB; Carpenter CB; Kirkman RL
Ann Surg; 1984 Nov; 200(5):605-13. PubMed ID: 6385881
[TBL] [Abstract][Full Text] [Related]
34. Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood.
Moyer TP; Post GR; Sterioff S; Anderson CF
Mayo Clin Proc; 1988 Mar; 63(3):241-7. PubMed ID: 3278174
[TBL] [Abstract][Full Text] [Related]
35. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.
Thierry A; Le Meur Y; Ecotière L; Abou-Ayache R; Etienne I; Laurent C; Vuiblet V; Colosio C; Bouvier N; Aldigier JC; Rerolle JP; Javaugue V; Gand E; Bridoux F; Essig M; Hurault de Ligny B; Touchard G
Transpl Int; 2016 Jan; 29(1):23-33. PubMed ID: 26729582
[TBL] [Abstract][Full Text] [Related]
36. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients.
Schulak JA; Mayes JT; Moritz CE; Hricik DE
Transplantation; 1990 Feb; 49(2):327-32. PubMed ID: 2407003
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for second renal allografts immunosuppressed with cyclosporine.
Almond PS; Matas AJ; Gillingham K; Troppmann C; Payne W; Dunn D; Sutherland D; Najarian JS
Transplantation; 1991 Aug; 52(2):253-8. PubMed ID: 1871798
[TBL] [Abstract][Full Text] [Related]
38. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506.
Swenson JM; Fricker FJ; Armitage JM
J Am Coll Cardiol; 1995 Apr; 25(5):1183-8. PubMed ID: 7534779
[TBL] [Abstract][Full Text] [Related]
39. Hyperuricemia after renal transplantation.
Gores PF; Fryd DS; Sutherland DE; Najarian JS; Simmons RL
Am J Surg; 1988 Nov; 156(5):397-400. PubMed ID: 3056057
[TBL] [Abstract][Full Text] [Related]
40. Arterial hypertension in heart transplant recipients treated with triple-drug immunosuppressive therapy.
Olivari MT; Antolick A; Ring WS
J Heart Transplant; 1989; 8(1):34-9. PubMed ID: 2647929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
